Why Amedisys (AMED) is a Top Value Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.
While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.
Why Investors Should Pay Attention to This Value Stock
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.
Amedisys (AMED)
Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, as well as various rehabilitative programs. It provides hospice services to patients through an interdisciplinary care team which includes nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains. Amedisys was founded in 1982 and is headquartered in Baton Rouge, LA.
AMED sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Medical - Outpatient and Home Healthcare industry's P/E of 21.3X, shares of Amedisys are trading at a forward P/E of 20.3X. AMED also has a PEG Ratio of 4.3, a Price/Cash Flow ratio of 15.1X, and a Price/Sales ratio of 1.4X.
Many value investors pay close attention to a company's earnings as well. For AMED, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.05 to $4.54 per share for 2024. Per share AMED boasts an average earnings surprise of 6.4%.
AMED should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amedisys, Inc. (AMED) : Free Stock Analysis Report
